RECORD // Company

Context Therapeutics Inc.

Formerly: Context Therapeutics LLC

Built 2026-11-22T00:12:01Z from public sources · JSON · Open the company profile

ASK THE RECORDS

Ask

COMPANY

Records for this company (2 joined by official identifier)

Every record below is joined to this company by a hard identifier: its SEC registrant record or its GLEIF ownership tree. Each line says how. Built 2026-11-18 13:42:42. Beta: records that match only by name are held apart until name matching is verified.

Gleif lei (1)
SEC EDGAR (1)
Matched by name only, not merged (1)

These records carry the same exact name as this company, but a name alone is not proof, so Seraphix holds them apart until name matching is verified (score due 11-21).

  • Context Therapeutics Inc. · Ctgov · same registered legal name as 'Context Therapeutics Inc.' Possible match based on name, not a shared identifier. Compare the records. Compare

2 VALUES · 10-Q · EACH LINKS TO ITS FILING

Latest quarter

Latest report: 10-Q for the period ended 2026-09-30, filed 2026-11-10 · accession 0001628280-26-072730

ItemValuePeriodFormFiledAccessionReport
Net income (loss)$-7,623,7063 months ended 2026-09-3010-Q2026-11-100001628280-26-0727302026-11-22 00:12 UTCReport an error
Cash and cash equivalents$34,410,919at 2026-09-3010-Q2026-11-100001628280-26-0727302026-11-22 00:12 UTCReport an error

Negative as reported in the filing.

Not in this report's XBRL: Revenue, Interest expense.

Values as filed in XBRL (SEC company facts); quarterly values are the filer's 3-month figures, never derived.

IDS

Identifiers

SEC CIK
0001842952
Ticker
CNTX
EIN
863738787
CUSIP
21077P108
Record ID
sx:sec:0001842952

OTHER SITES · YOUR CLICK · THEY SHOW THEIR OWN DATA

Open in

Open in…

Each link opens the other site in a new tab, with this company filled in. That site shows its own data under its own terms; Seraphix stores none of it. Seraphix counts clicks per link, nothing about who clicked.

32 FACTS · EACH LINKS TO ITS FILING

Facts

FactValueAs ofSourceRetrievedReport
SEC entity typeoperating2026-11-10SEC EDGAR company profile2026-11-22 00:12 UTCReport an error
SIC industry2834 Pharmaceutical Preparations2026-11-10SEC EDGAR company profile2026-11-22 00:12 UTCReport an error
State of incorporationDE2026-11-10SEC EDGAR company profile2026-11-22 00:12 UTCReport an error
Fiscal year end (MMDD)12312026-11-10SEC EDGAR company profile2026-11-22 00:12 UTCReport an error
Business address2001 MARKET STREET, SUITE 3915 UNIT #15, PHILADELPHIA, PA, 191032026-11-10SEC EDGAR company profile2026-11-22 00:12 UTCReport an error
ExchangesNasdaq2026-11-10SEC EDGAR company profile2026-11-22 00:12 UTCReport an error
Net income (loss) (fiscal year ended 2025-12-31)$-36,123,6152025-12-3110-K, XBRL NetIncomeLoss2026-11-22 00:12 UTCReport an error
Total assets (at 2025-12-31)$68,493,7682025-12-3110-K, XBRL Assets2026-11-22 00:12 UTCReport an error
Stockholders' equity (at 2025-12-31)$60,473,7272025-12-3110-K, XBRL StockholdersEquity2026-11-22 00:12 UTCReport an error
Cash and cash equivalents (at 2025-12-31)$65,995,2282025-12-3110-K, XBRL CashAndCashEquivalentsAtCarryingValue2026-11-22 00:12 UTCReport an error
Operating cash flow (fiscal year ended 2025-12-31)$-26,385,3802025-12-3110-K, XBRL NetCashProvidedByUsedInOperatingActivities2026-11-22 00:12 UTCReport an error
Capital expenditures (property, plant and equipment) (fiscal year ended 2025-12-31)$33,9482025-12-3110-K, XBRL PaymentsToAcquirePropertyPlantAndEquipment2026-11-22 00:12 UTCReport an error
Operating lease liabilities (at 2025-12-31)$100,0002025-12-3110-K, XBRL OperatingLeaseLiability2026-11-22 00:12 UTCReport an error
Form D total offering amount (D filed 2024-05-16)$99,998,2502024-05-16D2026-11-22 00:12 UTCReport an error
Form D total amount sold (D filed 2024-05-16)$99,992,7672024-05-16D2026-11-22 00:12 UTCReport an error
Form D industry groupPharmaceuticals2024-05-16D2026-11-22 00:12 UTCReport an error
Form D revenue rangeNo Revenues2024-05-16D2026-11-22 00:12 UTCReport an error
Form D date of first sale2024-05-062024-05-16D2026-11-22 00:12 UTCReport an error
8-K Item 7.01, Regulation FD Disclosure (filed 2026-11-10)On November 10, 2026, Context Therapeutics Inc. (the "Company") issued a press release announcing its third quarter 2026 operating and financial results and providing updates on its pipeline progress. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference into this Item 7.01. The information in this Item 7.01, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any of the…2026-11-10SEC EDGAR 8-K 0001628280-26-072768 (text as filed, excerpt)2026-11-22 00:12 UTCReport an error
8-K Item 8.01, Other Events (filed 2026-11-10)On November 10, 2026, the Company updated its corporate presentation (the "Corporate Presentation"). A copy of the Corporate Presentation is filed as Exhibit 99.2 to this Current Report on Form 8-K and is incorporated by reference into this Item 8.01.2026-11-10SEC EDGAR 8-K 0001628280-26-072768 (text as filed, excerpt)2026-11-22 00:12 UTCReport an error
8-K Item 7.01, Regulation FD Disclosure (filed 2026-08-05)On August 5, 2026, Context Therapeutics Inc. (the "Company") updated its corporate presentation for use in meetings with investors, analysts and others. A copy of the corporate presentation is filed as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference. The information in this Item 7.01, and Exhibit 99.1 attached hereto, are being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act…2026-08-05SEC EDGAR 8-K 0001628280-26-053378 (text as filed, excerpt)2026-11-22 00:12 UTCReport an error
8-K Item 3.01, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing (filed 2026-07-31)On July 29, 2026, Context Therapeutics Inc. (the “Company”) received written notice (the “Notification Letter”) from the Nasdaq Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) stating that the Company was not in compliance with Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Rule”) because the Company’s common stock failed to maintain a minimum closing bid price of $1.00 per share for 30 consecutive business days. The Notification Letter has no immediate effect on the Nasdaq listing or trading of the Company’s common stock. The Notification Letter provides an initial 180 calendar day period, or until January 25, 2027, in which to regain…2026-07-31SEC EDGAR 8-K 0001628280-26-051399 (text as filed, excerpt)2026-11-22 00:12 UTCReport an error
Largest institutional holder #1 (13F as filed): Deep Track Capital, LP$4,109,5812026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 00:12 UTCReport an error
Largest institutional holder #2 (13F as filed): Nextech Invest Ltd.$4,109,5812026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 00:12 UTCReport an error
Largest institutional holder #3 (13F as filed): Soleus Capital Management, L.P.$3,912,2742026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 00:12 UTCReport an error
Largest institutional holder #4 (13F as filed): BlackRock, Inc.$3,417,1482026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 00:12 UTCReport an error
Largest institutional holder #5 (13F as filed): Avidity Partners Management LP$2,768,5402026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 00:12 UTCReport an error
Largest institutional holder #6 (13F as filed): FRANKLIN RESOURCES INC$2,106,6692026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 00:12 UTCReport an error
Largest institutional holder #7 (13F as filed): VANGUARD CAPITAL MANAGEMENT LLC$1,901,3572026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 00:12 UTCReport an error
Largest institutional holder #8 (13F as filed): Octagon Capital Advisors LP$1,689,3952026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 00:12 UTCReport an error
Largest institutional holder #9 (13F as filed): Blue Owl Capital Holdings LP$1,625,1512026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 00:12 UTCReport an error
Largest institutional holder #10 (13F as filed): TCG Crossover Management, LLC$1,485,9452026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 00:12 UTCReport an error

EVERY DATED RECORD, NEWEST FIRST

Timeline

WHAT IS NOT HERE

Gaps

SOURCES AND LICENSE

Sources

CC BY 4.0 -- credit Seraphix Systems.

API

Use this record

Records are free to read and reuse under CC BY 4.0 -- credit Seraphix Systems. The same records as JSON: GET /v1/search?q= and GET /v1/record/<id> (without a key, up to 50 record lookups a day per visitor). No key: single records, pages, feeds and bulk files are free; cross-company search and the live stream cost $0.002 a call via x402. Free key: 100 calls a month, no card. Get a free key or a paid key; send Authorization: Bearer <key>.